The IP-protected, novel formulation for WoundForce™ is based on the ability of the product’s active pharmaceutical ingredient – urea – to disaggregate and denature various types of necrotic material, which is then encapsulated and wicked away from the wound by a gentle detergent with a high affinity for this type of material. The formulation is further enhanced by a physiological buffer and hydrocolloidal base to promote an optimal environment within the wound bed.
Because the action of the drug is not based on enzymes, it does not have limitations common to those forms of products such as reduced efficacy outside of a narrow pH range, reduced efficacy related to interactions with common wound antimicrobials, and limited range of utility only on specific necrotic material types. This should give caregivers and patients alike the confidence they need in the efficacy of the drug, regardless of the varying conditions surrounding the wound.
This drug has not yet been approved by the FDA
3-Step Mode of Action
Chronic wounds often have necrotic material made up of soft and hard eschar
(an aggregate of denatured proteins), which must be removed for chronic wounds to heal.
A low concentration of urea selectively disentangles aggregated proteins that form the various types of necrotic material (including fibrin, elastin and collagen)
HECAMEG – a gentle zwitterionic detergent – envelopes the disentangled proteins
Wound exudate and/or cleansing solution dilutes and breaks the HECAMEG micelles, releasing the eschar proteins and moving them away from the wound bed.
WoundForce™ is a broad-spectrum topical drug candidate, whose formulation is protected by a pending patent. Key claims regarding the mechanism of action are reported above.
Disrupting a Monopoly Market
The standard of care, Santyl, is a monopoly drug with ~$320m in revenue, within a $1.1b market opportunity.
In-vitro and porcine data indicate that WoundForce™
is has a broader spectrum
and fewer contra indications than Santyl.
capture market share by
while also expanding
is currently the only FDA-approved drug for wound debridement:a monopoly worth $320m in sales.
usage (and market opportunity) is limited by pH range efficacy and non-compatibility with common antimicrobials.
WoundForce™ fills a huge market gap, by providing a more effective clinical solution that does not have the same usage limitations as Santyl, according to pre-clinical studies.
WoundForce™ targets a $1.1B market in which Santyl is the only player and has captured just one third of the opportunity.
Diabetic Foot Ulcers
WOUND DEMOGRAPHICS IN THE US